nach oben

Inflammopharmacology

Erschienen in:

05.08.2020 | Review

The advances of methotrexate resistance in rheumatoid arthritis

verfasst von: Jun Yu, Peng Zhou

Erschienen in: Inflammopharmacology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease, which is characterized by a chronic fluctuating course and immune dysfunction, resulting in affecting the health and life quality of RA patients. Methotrexate (MTX), as the standard gold treatment of RA, has received more and more clinical applications and basic pharmacological research. In several observational studies, MTXR, and treatment responses in RA patients show that the ratio of MTXR and non- response is about 30%–50%, namely MTX resistance (MTXR). Extensive efforts have been made into the investigation of the mechanism and effective biomarkers in MTXR of RA. In this paper, we discuss the recent findings regarding the critical signaling pathways of MTXR in RA. Provide research targets and directions for a drug therapy that develop preventive strategies and effective treatments of MTXR.

Ally MM, Hodkinson B, Meyer PW, Musenge E, Tintinger GR, Tikly M, Anderson R (2015) Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. BMC Musculoskelet Disord 16:130. https://doi.org/10.1186/s12891-015-0587-1CrossRefPubMedPubMedCentral

Association CR (2018) 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Chin J Intern Med 57:242–251

Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR (2002) Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587:164–173. https://doi.org/10.1016/s0925-4439(02)00079-0CrossRefPubMed

Bobbio-Pallavicini F, Caporali R, Alpini C, Moratti R, Montecucco C (2007) Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann N Y Acad Sci 1109:287–295. https://doi.org/10.1196/annals.1398.034CrossRefPubMed

Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB (1995) Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 24:411–421. https://doi.org/10.1016/s0049-0172(95)80009-3CrossRefPubMed

Braun J et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthr Rheum 58:73–81. https://doi.org/10.1002/art.23144CrossRef

Brown JM et al (2017) Detection and characterisation of bone destruction in murine rheumatoid arthritis using statistical shape models. Med Image Anal 40:30–43. https://doi.org/10.1016/j.media.2017.05.006CrossRefPubMed

Bunni M, Doig MT, Donato H, Kesavan V, Priest DG (1988) Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells. Cancer Res 48:3398–3404PubMed

Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916. https://doi.org/10.1056/NEJM200103223441207CrossRefPubMed

Cribbs AP et al (2015) Methotrexate restores regulatory T cell function through demethylation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheumatol 67:1182–1192. https://doi.org/10.1002/art.39031CrossRefPubMed

Cronstein BN, Sitkovsky M (2017) Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol 13:41–51. https://doi.org/10.1038/nrrheum.2016.178CrossRefPubMed

Cronstein BN, Naime D, Ostad E (1993) The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92:2675–2682. https://doi.org/10.1172/JCI116884CrossRefPubMedPubMedCentral

de Andres MC, Perez-Pampin E, Calaza M, Santaclara FJ, Ortea I, Gomez-Reino JJ, Gonzalez A (2015) Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. Arthritis Res Ther 17:233. https://doi.org/10.1186/s13075-015-0748-5CrossRefPubMedPubMedCentral

Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766–2774. https://doi.org/10.1002/art.20460CrossRefPubMed

Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ, Kremer JM (2009) Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genom 19:935–944. https://doi.org/10.1097/FPC.0b013e32833315d1CrossRef

Dong X, Gan Y, Ding L, Zeng F, Ding D (2019) Effect of jiawei fengshining on synovial cell apoptosis and TGF-beta1/Smad signaling pathway in rats with rheumatoid arthritis evid based complement. Alternat Med 2019:8614034. https://doi.org/10.1155/2019/8614034CrossRef

Dulic S et al (2017) T-cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy. Mediat Inflamm 2017:6894374. https://doi.org/10.1155/2017/6894374CrossRef

Ercan A et al (2010) Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum 62:2239–2248. https://doi.org/10.1002/art.27533CrossRefPubMedPubMedCentral

Felson DT (2016) Safety of nonsteroidal antiinflammatory drugs. N Engl J Med 375:2595–2596. https://doi.org/10.1056/NEJMe1614257CrossRefPubMed

Foell D, Roth J (2004) Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 50:3762–3771. https://doi.org/10.1002/art.20631CrossRefPubMed

Gao M, Zheng J, Zheng C, Huang Z, Huang Q (2020) Theacrine alleviates chronic inflammation by enhancing TGF-beta-mediated shifts via TGF-beta/SMAD pathway in Freund’s incomplete adjuvant-induced rats. Biochem Biophys Res Commun 522:743–748. https://doi.org/10.1016/j.bbrc.2019.11.126CrossRefPubMed

Gosselt HR, van Zelst BD, de Rotte M, Hazes JMW, de Jonge R, Heil SG (2019) Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients. Arthritis Res Ther 21:157. https://doi.org/10.1186/s13075-019-1936-5CrossRefPubMedPubMedCentral

Grabar PB, Rojko S, Logar D, Dolzan V (2010) Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway. Ann Rheum Dis 69:931–932. https://doi.org/10.1136/ard.2009.111567CrossRefPubMed

Green PG, Basbaum AI, Helms C, Levine JD (1991) Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat. Proc Natl Acad Sci USA 88:4162–4165. https://doi.org/10.1073/pnas.88.10.4162CrossRefPubMedPubMedCentral

Halilova KI, Brown EE, Morgan SL, Bridges SL Jr, Hwang MH, Arnett DK, Danila MI (2012) Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol 2012:978396. https://doi.org/10.1155/2012/978396CrossRefPubMedPubMedCentral

Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770. https://doi.org/10.1038/nrd2638CrossRefPubMedPubMedCentral

Herrath J et al (2011) The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur J Immunol 41:2279–2290. https://doi.org/10.1002/eji.201041004CrossRefPubMed

Ikemura K et al (2019) Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. Sci Rep 9:20359. https://doi.org/10.1038/s41598-019-56900-2CrossRefPubMedPubMedCentral

Inoue K, Yuasa H (2014) Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet 29:12–19. https://doi.org/10.2133/dmpk.dmpk-13-rv-119CrossRefPubMed

Jekic B et al (2013) Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol 69:377–383. https://doi.org/10.1007/s00228-012-1341-3CrossRefPubMed

Kim YI, Logan JW, Mason JB, Roubenoff R (1996) DNA hypomethylation in inflammatory arthritis: reversal with methotrexate. J Lab Clin Med 128:165–172. https://doi.org/10.1016/s0022-2143(96)90008-6CrossRefPubMed

Lampropoulos CE et al (2015) Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clin Exp Rheumatol 33:216–224PubMed

Leclerc GJ, Mou C, Leclerc GM, Mian AM, Barredo JC (2010) Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. Leukemia 24:552–562. https://doi.org/10.1038/leu.2009.282CrossRefPubMed

Li H et al (2018) Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge. Bioorg Med Chem 26:2674–2685. https://doi.org/10.1016/j.bmc.2018.04.035CrossRefPubMed

Liu YM, Chen JW, Chen LX, Xie X, Mao N (2016) Overexpression of P-glycoprotein on fibroblast-like synoviocytes in refractory rheumatoid arthritis patients: a potential mechanism for multidrug resistance in rheumatoid arthritis treatment. Genet Mol Res. https://doi.org/10.4238/gmr.15027927CrossRefPubMed

Lubberts E (2015) Role of T lymphocytes in the development of rheumatoid arthritis. Implications for treatment. Curr Pharm Des 21:142–146. https://doi.org/10.2174/1381612820666140825122247CrossRefPubMed

Ma D et al (2019) Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. Int Immunopharmacol 74:105687. https://doi.org/10.1016/j.intimp.2019.105687CrossRefPubMed

Marotte H, Maslinski W, Miossec P (2005) Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 7:R149–155. https://doi.org/10.1186/ar1465CrossRefPubMed

Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P (2008) Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 58:1258–1263. https://doi.org/10.1002/art.23430CrossRefPubMed

Massague J, Wotton D (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19:1745–1754. https://doi.org/10.1093/emboj/19.8.1745CrossRefPubMedPubMedCentral

Michelsen B et al (2017) Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 76:1906–1910. https://doi.org/10.1136/annrheumdis-2017-211284CrossRefPubMed

Micsik T, Lorincz A, Gal J, Schwab R, Petak I (2015) MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients. Diagn Pathol 10:216. https://doi.org/10.1186/s13000-015-0447-1CrossRefPubMedPubMedCentral

Montesinos MC, Desai A, Cronstein BN (2006) Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res Ther 8:R53. https://doi.org/10.1186/ar1914CrossRefPubMedPubMedCentral

Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernandez P, Cronstein BN (2007) The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis Rheum 56:1440–1445. https://doi.org/10.1002/art.22643CrossRefPubMed

Mori S, Hirose J, Yonemura K (2010) Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis. Clin Rheumatol 29:1357–1366. https://doi.org/10.1007/s10067-010-1454-yCrossRefPubMed

Nesher G, Moore TL (1990) The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum 33:954–959. https://doi.org/10.1002/art.1780330706CrossRefPubMed

Nesher G, Mates M, Zevin S (2003) Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 48:571–572. https://doi.org/10.1002/art.10766CrossRefPubMed

Odink K et al (1987) Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 330:80–82. https://doi.org/10.1038/330080a0CrossRefPubMed

Ostrowska M, Maslinski W, Prochorec-Sobieszek M, Nieciecki M, Sudol-Szopinska I (2018) Cartilage and bone damage in rheumatoid arthritis. Reumatologia 56:111–120. https://doi.org/10.5114/reum.2018.75523CrossRefPubMedPubMedCentral

Pachot A et al (2007) Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol 34:2158–2161PubMed

Patro PS, Singh A, Misra R, Aggarwal A (2016) Myeloid-related protein 8/14 levels in rheumatoid arthritis: marker of disease activity and response to methotrexate. J Rheumatol 43:731–737. https://doi.org/10.3899/jrheum.150998CrossRefPubMed

Peres RS et al (2015) Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. Proc Natl Acad Sci USA 112:2509–2514. https://doi.org/10.1073/pnas.1424792112CrossRefPubMedPubMedCentral

Peres RS et al (2018) TGF-beta signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis. J Autoimmun 90:49–58. https://doi.org/10.1016/j.jaut.2018.01.004CrossRefPubMed

Perez-Guerrero EE et al (2018) Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis. Inflammopharmacology. https://doi.org/10.1007/s10787-018-0529-2CrossRefPubMed

Ponchel F et al (2014) An immunological biomarker to predict MTX response in early RA. Ann Rheum Dis 73:2047–2053. https://doi.org/10.1136/annrheumdis-2013-203566CrossRefPubMed

Priess M, Goddeke H, Groenhof G, Schafer LV (2018) Molecular mechanism of ATP hydrolysis in an ABC transporter. ACS Cent Sci 4:1334–1343. https://doi.org/10.1021/acscentsci.8b00369CrossRefPubMedPubMedCentral

Rayl EA, Moroson BA, Beardsley GP (1996) The human purH gene product, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. Cloning, sequencing, expression, purification, kinetic analysis, and domain mapping. J Biol Chem 271:2225–2233. https://doi.org/10.1074/jbc.271.4.2225CrossRefPubMed

Rose MG, Farrell MP, Schmitz JC (2002) Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer 1:220–229. https://doi.org/10.3816/CCC.2002.n.003CrossRefPubMed

Saevarsdottir S et al (2011) Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 70:469–475. https://doi.org/10.1136/ard.2010.139212CrossRefPubMed

Selga E, Oleaga C, Ramirez S, de Almagro MC, Noe V, Ciudad CJ (2009) Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med 1:83. https://doi.org/10.1186/gm83CrossRefPubMedPubMedCentral

Sergeant JC et al. (2018) Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS) Arthritis Res Ther 20:147 https://doi.org/10.1186/s13075-018-1645-5

Sharma S et al (2009) Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics 19:823–828. https://doi.org/10.1097/fpc.0b013e328331b53eCrossRefPubMed

Shevach EM, Tran DQ, Davidson TS, Andersson J (2008) The critical contribution of TGF-beta to the induction of Foxp3 expression and regulatory T cell function. Eur J Immunol 38:915–917. https://doi.org/10.1002/eji.200738111CrossRefPubMedPubMedCentral

Singh JA et al (2016) 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:1–25. https://doi.org/10.1002/acr.22783CrossRef

Slauenwhite D, McAlpine SM, Hanly JG, Malik A, Haidl ID, Marshall JS, Issekutz TB (2020) Type 2 polarized t cell phenotype is associated with methotrexate non-response in patients with rheumatoid arthritis. Arthritis Rheumatol. https://doi.org/10.1002/art.41223CrossRefPubMed

Smolen JS et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2019-216655CrossRefPubMed

Stamp LK, Hazlett J, Highton J, Hessian PA (2013) Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue. J Rheumatol 40:1519–1522. https://doi.org/10.3899/jrheum.130066CrossRefPubMed

Stempak JM, Sohn KJ, Chiang EP, Shane B, Kim YI (2005) Cell and stage of transformation-specific effects of folate deficiency on methionine cycle intermediates and DNA methylation in an in vitro model. Carcinogenesis 26:981–990. https://doi.org/10.1093/carcin/bgi037CrossRefPubMed

Sun W et al (2019) Correlations between the polymorphism of +869T/C in TGF-β1 and rheumatoid arthritis. J Musculoskelet Neuronal Interact 19:127–132PubMedPubMedCentral

Tengstrand B, Ahlmen M, Hafstrom I (2004) The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol 31:214–222PubMed

Tsujimura S, Tanaka Y (2015) Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis World. J Exp Med 5:225–231. https://doi.org/10.5493/wjem.v5.i4.225CrossRef

van der Heijden JW et al (2009) Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum 60:669–677. https://doi.org/10.1002/art.24354CrossRefPubMed

van Hamburg JP et al (2011) Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 63:73–83. https://doi.org/10.1002/art.30093CrossRefPubMed

van Vollenhoven RF et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374:459–466. https://doi.org/10.1016/s0140-6736(09)60944-2CrossRefPubMed

Varani K, Massara A, Vincenzi F, Tosi A, Padovan M, Trotta F, Borea PA (2009) Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum 60:2880–2891. https://doi.org/10.1002/art.24794CrossRefPubMed

Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, Borea PA (2011) A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther 13:R197. https://doi.org/10.1186/ar3527CrossRefPubMedPubMedCentral

Verburg RJ et al (2005) Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Ann Rheum Dis 64:1397–1405. https://doi.org/10.1136/ard.2004.033332CrossRefPubMedPubMedCentral

Vilca I et al (2010) Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis 69:1479–1483. https://doi.org/10.1136/ard.2009.120840CrossRefPubMed

Visser K et al (2008) Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 67:1194–1195. https://doi.org/10.1136/ard.2008.088070CrossRefPubMed

Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, Schneider E (2000) Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 60:3514–3521PubMed

Wang YC, Chiang EP (2012) Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo. Mol Med 18:423–432. https://doi.org/10.2119/molmed.2011.00048CrossRefPubMed

Wang HX et al (2018) Dysregulated ICOS(+) proinflammatory and suppressive regulatory T cells in patients with rheumatoid arthritis. Exp Ther Med 16:3728–3734. https://doi.org/10.3892/etm.2018.6657CrossRefPubMedPubMedCentral

Wang J, Mao N, Xie X, Li S, Chen WJ (2019) High expression of multidrug resistance gene-1 can aggravate resistance to methotrexate in rheumatoid arthritis patients. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Acad Med Sin 41:595–600. https://doi.org/10.3881/j.issn.1000-503x.10927CrossRef

Wehrens EJ et al (2011) Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood 118:3538–3548. https://doi.org/10.1182/blood-2010-12-328187CrossRefPubMed

Wei W (2016) Soft regulation of inflammatory immune response. Chin Pharmacol Bull 32:297–303

Wojtuszkiewicz A et al (2015) Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. J Hematol Oncol 8:61. https://doi.org/10.1186/s13045-015-0158-9CrossRefPubMedPubMedCentral

Wolf J, Stranzl T, Filipits M, Pohl G, Pirker R, Leeb B, Smolen JS (2005) Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis 64:564–568. https://doi.org/10.1136/ard.2003.014985CrossRefPubMed

Wong LH, Flibotte S, Sinha S, Chiang J, Giaever G, Nislow C (2017) Genome-wide screen reveals sec21 mutants of saccharomyces cerevisiae are methotrexate-resistant. G3 (Bethesda) 7:1251–1257. https://doi.org/10.1534/g3.116.038117CrossRef

Wu YJ, Wang C, Wei W (2018) The effects of DMARDs on the expression and function of P-gp, MRPs, BCRP in the treatment of autoimmune diseases. Biomed Pharmacother 105:870–878. https://doi.org/10.1016/j.biopha.2018.06.015CrossRefPubMed

Yao X et al (2017) Over-expression of mdr1/P-gp is associated with methotrexate resistance in patients with rheumatoid arthritis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. Chin J Cell Mol Immunol 33:815–819

Youssef P, Roth J, Frosch M, Costello P, Fitzgerald O, Sorg C, Bresnihan B (1999) Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol 26:2523–2528PubMed

Yu J, Zhou P, Asenso J, Yang XD, Wang C, Wei W (2016) Advances in plant-based inhibitors of P-glycoprotein. J Enzyme Inhib Med Chem 31:867–881. https://doi.org/10.3109/14756366.2016.1149476CrossRefPubMed

Yu MB, Firek A, Langridge WHR (2018) Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacology 26:699–708. https://doi.org/10.1007/s10787-018-0459-zCrossRefPubMed

Titel: The advances of methotrexate resistance in rheumatoid arthritis
verfasst von: Jun Yu
Peng Zhou
Publikationsdatum: 05.08.2020
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 5/2020
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-020-00741-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Conditional nutrition (I): concerning zinc as a beneficial but variable regulator of inflammation and experimental arthritis

APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without supressing antimicrobial ability, and inhibits TNFα expression and signalling

Methyl 3,4,5-trimethoxycinnamate suppresses inflammation in RAW264.7 macrophages and blocks macrophage–adipocyte interaction

Baicalein exerts neuroprotective effect against ischaemic/reperfusion injury via alteration of NF-kB and LOX and AMPK/Nrf2 pathway

Commemorating life and works of the late Barrie Vernon-Roberts and leading Australian scientists in the fields of inflammation and pharmacotherapy of inflammatory diseases

COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties